1.72 USD
▼-0.06-3.37%
盘后 1.74 +1.16%
2026-09-15
市值
$583.88M
市盈率
—
EPS
-0.65
股息率
—
52 周区间
1.04 – 4.46
成交量
3.14M
Beta
0.48
目标价
9.00
52W 低 1.0452W 高 4.46
价格走势
公司简介
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ...